The development of combination immunotherapy based on the mediation of regulatory
mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep …

Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Background Despite immunotherapy advancements for patients with advanced or metastatic
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …

To address urgent tasks in the treatment of advanced deep‐seated tumors, a 980 nm
absorbing agent with aggregation‐induced emission tendency, namely TPE‐BT‐BBTD …

To address the low response rate to immune checkpoint blockade (ICB) therapy, we
propose a specific promoter-driven CRISPR/Cas9 system, F-PC/pHCP, that achieves …

Immunotherapy, including use of checkpoint inhibitors against PD-1, PD-L1, and CTLA-4,
forms the backbone of oncologic management for the majority of non-small cell lung …

Background Camrelizumab plus chemotherapy significantly prolonged progression-free
survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line …

Previous small-size studies reported BRAF-mutated NSCLC patients have comparable
sensitivity to immune checkpoint inhibitors (ICIs). However, how BRAF mutation affects the …